Carregant...

Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use

Immune checkpoint inhibition (ICI) is a promising cancer therapy, which has progressed rapidly from a preclinical concept to clinical implementation. Commonly considered targets in ICI are CTLA-4, PD-1/PD-L1, and LAG-3, and the list grows. As ICI is generally only beneficial for a subset of patients...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Biomolecules
Autors principals: Lecocq, Quentin, Zeven, Katty, De Vlaeminck, Yannick, Martens, Sandrina, Massa, Sam, Goyvaerts, Cleo, Raes, Geert, Keyaerts, Marleen, Breckpot, Karine, Devoogdt, Nick
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2019
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6843898/
https://ncbi.nlm.nih.gov/pubmed/31569553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biom9100548
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!